货号:A176170
同义名:
左旋咪唑碱
/ (-)-Tetramisole
Levamisole是一种免疫调节剂,作为碱性磷酸酶的竞争性抑制剂,能够调节免疫反应,促进免疫系统的功能。它被广泛应用于增强免疫活性,并有应用于复发性疱疹感染研究领域的潜力。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Levamisole is an anthelmintic agent with immunomodulatory effects[1]. Treatment of human dendritic cells with 1 μM levamisole significantly promoted the secretion of IL-12 p40 and IL-10 secretion compared to the control group. Levamisole at 1 μM also further enhanced lipopolysaccharide (10 ng/mL)-induced production of IL-12 p40 and IL-10 in human dendritic cells. Levamisole-treated dendritic enhanced T cell activation towards type 1 cytokine balance. The NF-κB and JNK pathways were involved in levamisole-induced secretion of IL-12 p40 in dendritic cells[2]. In mice infected with 1,000 infective T canis larvae, subcutaneous administration of levamisole hydrochloride at a dose of 12 mg/kg/day from days 15 to 28 of infection decreased the infection in all organs[3]. |
| 作用机制 | Levamisole exerts its immunomodulatory effects through cholinergic activity on T lymphocytes, resulting in an increase in the level of cyclic guanosine monophosphate in lymphocytes[1]. |
| Concentration | Treated Time | Description | References | |
| AS MSCs | 100 μM | Inhibition of accelerated mineralization in AS MSCs | J Clin Invest. 2019 Dec 2;129(12):5357-5373 | |
| CD4+CD25-T cells | 8 mg/ml, 40 mg/ml, 200 mg/ml | 72 hours | suppressed T cell proliferation | Front Immunol. 2022 Jul 14;13:907808 |
| DC2.4 cells | 8 mg/ml, 40 mg/ml, 200 mg/ml | 48 hours | inhibited TLR7 agonist-induced proinflammatory cytokine production | Front Immunol. 2022 Jul 14;13:907808 |
| BMNCs (bone marrow nucleated cells) | 40 mg/ml | 48 hours | downregulated genes related to APCs and T cells | Front Immunol. 2022 Jul 14;13:907808 |
| Regulatory T cells (Tregs) | 8 mg/ml, 40 mg/ml, 200 mg/ml | 72 hours | increased the proportion of Tregs | Front Immunol. 2022 Jul 14;13:907808 |
| vascular smooth muscle cells (VSMCs) | 200 μmol/L | The combination of TNAP inhibitor levamisole and eNTPD inhibitor ARL67156 increased extracellular pyrophosphate synthesis in LmnaG609G/ +VSMCs 2-fold, reduced pyrophosphate hydrolysis by 91%, and decreased calcium accumulation by 92%. | Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23698-23704 | |
| Human microvascular endothelial cells (HMVECs) | 100 μg | 24 hours | To assess the cytotoxic effects of Levamisole-induced NETs on endothelial cells. Results showed that Levamisole-induced NETs significantly enhanced endothelial cell apoptosis. | JCI Insight. 2017 Feb 9;2(3):e89780 |
| Peripheral blood neutrophils from healthy human subjects | 100 μM | 3 hours | To evaluate the effect of Levamisole on neutrophil extracellular trap (NET) formation. Results showed that Levamisole significantly increased NET formation, which was dependent on the activation of NADPH oxidase and PAD4. | JCI Insight. 2017 Feb 9;2(3):e89780 |
| Administration | Dosage | Frequency | Description | References | ||
| CB6F1 mice | Immune-mediated bone marrow failure model | Oral | 20 mg/kg | Once daily starting from day 0 until the mice died | Improved pancytopenia and prolonged survival, suppressed effector T cells and promoted regulatory T-cell expansion | Front Immunol. 2022 Jul 14;13:907808 |
| Mice | LmnaG609G/ +mouse model | Intraperitoneal injection | 0.2 mg/kg | Every 2 days, starting from 8 weeks of age until death or euthanasia | Combined treatment with ATP, levamisole, and ARL67156 significantly extended the lifespan of LmnaG609G/ +mice (from 38.2 to 42.8 weeks, 11.9%) and reduced aortic calcification (from 837.4 ±189.7 μg/g to 443.9±76.3 μg/g). | Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23698-23704 |
| Mice | Aortic ring model | In vitro culture | 100 μg | 15 minutes | To evaluate the effect of Levamisole-induced NETs on vascular relaxation. Results showed that Levamisole-induced NETs significantly impaired endothelium-dependent vasorelaxation. | JCI Insight. 2017 Feb 9;2(3):e89780 |
| Swiss albino male mice | Immunomodulatory activity evaluation model | Oral | 50 mg/kg | 14 days | Evaluate the immunomodulatory effects of Levamisole in mice, results showed Levamisole significantly increased thymus index (p<0.001). | Immunotargets Ther. 2024 Jan 23;13:15-27 |
| BALB/c male mice | Cyclophosphamide-induced immunosuppressed mouse model | Oral gavage | 10 mg/kg | Continuous for 28 days | To evaluate the immunomodulatory effects of levamisole hydrochloride on immunosuppressed mice. The results showed that levamisole hydrochloride significantly improved immune organ atrophy, restored intestinal morphology, and normalized cytokine levels, indicating enhanced immune function. | Front Immunol. 2025 Jan 27;16:1513531 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.90mL 0.98mL 0.49mL |
24.48mL 4.90mL 2.45mL |
48.95mL 9.79mL 4.90mL |
|
| CAS号 | 14769-73-4 |
| 分子式 | C11H12N2S |
| 分子量 | 204.29 |
| SMILES Code | C12=N[C@@H](C3=CC=CC=C3)CN1CCS2 |
| MDL No. | MFCD00792481 |
| 别名 | 左旋咪唑碱 ;(-)-Tetramisole |
| 运输 | 蓝冰 |
| InChI Key | HLFSDGLLUJUHTE-SNVBAGLBSA-N |
| Pubchem ID | 26879 |
| 存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 |
| 溶解方案 |
DMSO: 105 mg/mL(513.97 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1